Literature DB >> 19096808

[Indication and performance of endocrine surgery. The significance of molecular genetic examination].

P E Goretzki1, D Wirowski, K Schwarz, P Pohl, H Böhner, A Starke, B J Lammers.   

Abstract

The molecular genetic changes from certain endocrine tumors are already understood, reflecting as they do the etiology of these sporadic familial disorders. This already has clinical consequences to the treatment of familial endocrine tumors, which often appear in the course of syndromatic disorders. These consequences consist in slight changes to surgical technique, the search for other active and usually endocrinal tumors, and examination of family members for other gene carriers (of disease-specific mutations) and the most suitable prophylactic tumor therapy. In contrast, for sporadic endocrine tumors there exists far less clinically relevant knowledge. Starting with anamnesis and clinical findings of active endocrine tumors, we discuss the current possibilities for molecular genetic determination of disease-specific mutations (germline and tumor DNA) and their effect on surgical procedure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19096808     DOI: 10.1007/s00104-008-1615-6

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  34 in total

Review 1.  Dysfunction of the RET receptor in human cancer.

Authors:  M Santoro; F Carlomagno; R M Melillo; A Fusco
Journal:  Cell Mol Life Sci       Date:  2004-12       Impact factor: 9.261

2.  Subtotal adrenalectomy by the posterior retroperitoneoscopic approach.

Authors:  M K Walz; K Peitgen; B Saller; R M Giebler; S Lederbogen; K Nimtz; K Mann; F W Eigler
Journal:  World J Surg       Date:  1998-06       Impact factor: 3.352

3.  Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential?

Authors:  C Dotzenrath; K Cupisti; P E Goretzki; Q Yang; D Simon; C Ohmann; H D Röher
Journal:  Eur J Surg       Date:  2001-03

4.  Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.

Authors:  K Y Lam; C Y Lo; K W Chan; K Y Wan
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

Review 5.  Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.

Authors:  Raoul Tibes; Jonathan Trent; Razelle Kurzrock
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

6.  Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.

Authors:  Michael A Skinner; Jeffrey A Moley; William G Dilley; Kouros Owzar; Mary K Debenedetti; Samuel A Wells
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

7.  Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations.

Authors:  Michael T Collins; Nicholas J Sarlis; Maria J Merino; Jason Monroe; Susan E Crawford; Jonathan A Krakoff; Lori C Guthrie; Sandra Bonat; Pamela G Robey; Andrew Shenker
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

8.  Primary hyperparathyroidism in neonates and childhood. The French experience (1984-2004).

Authors:  Eric Mallet
Journal:  Horm Res       Date:  2008-01-08

9.  Natural course of small adrenal lesions in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study.

Authors:  S Schaefer; M Shipotko; S Meyer; D Ivan; K J Klose; J Waldmann; P Langer; P H Kann
Journal:  Eur J Endocrinol       Date:  2008-05       Impact factor: 6.664

10.  Hyperparathyroidism-jaw tumour syndrome.

Authors:  J D Chen; C Morrison; C Zhang; K Kahnoski; J D Carpten; B T Teh
Journal:  J Intern Med       Date:  2003-06       Impact factor: 8.989

View more
  1 in total

Review 1.  [Surgical therapy for thyroid gland malignancies].

Authors:  P E Goretzki; K Schwarz; B Lammers
Journal:  HNO       Date:  2013-01       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.